Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: Colby who wrote (758)	4/21/1998 7:18:00 PM
From: majormember	Read Replies (1) \| Respond to of 4140

Colby, Below is a compilation of posts which should answer your questions. You will see the procedures used to treat hyperopia from VISX and SNRS are entirely different...SNRS is not competing with VISX, and both the excimer and holmium laser will happily coexist in the same treatment room. Message 4121404 Best wishes, Skane

To: Colby who wrote (758)	4/21/1998 7:30:00 PM
From: Joe	Respond to of 4140

Perhaps the FDA will prefer to approve a non-invasive vs. invasive procedure, the FTC prefer the competition vs. the patent monopoly of Pillar Point Partners. Maybe there is a marketing stratagy in your message ... Sunrise should market directly to the consuming patients. While it makes sense for treatment centers with excimers to have a holmium LTK system, if for no other reason to correct their over treatments, perhaps the product will appeal to doctors that don't have excimers. What if the procedure is simple enough that the product will be sold to the optometrist. That is where the presbyope go anyway. There a lot of interesting questions to be answered in the SNRS saga.